Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
7 lessons
9mNAD+ is essential to cells. That does not make every NAD+ treatment effective. A practical guide to IV claims, oral precursors and what human studies actually measured.
9mMost peptide stigma is not a single hazard. It is three different risks that clinics mash together. Separate them and the conversation with counsel, pharmacy, and medical directors gets shorter.
8mIf your team cannot state the regulatory status of each compound in one clean sentence, the menu is not ready. Here is the three-band model clinics use before counsel finishes the memo.
6mAdamax is marketed as a modified Semax. Semax has decades of mostly Russian research. Adamax has essentially none in the published literature. Here's the honest comparison.
8mThe regulatory story matters because it changes what you can trust, what you should track, and why supply chain quality now sits beside mechanism in the BPC-157 debate.
7mThe biggest peptide trend in 2026 may not be a molecule. It may be oversight, sourcing quality, and the ability to separate evidence from marketing.
11mMelanotan 2 is a synthetic hormone analogue from a University of Arizona tanning program. It darkens skin in people, and it also causes erections, nausea and appetite changes. Its relatives became approved drugs. It never did, and the case-report record explains why regulators keep warning about it.
Also available at /blog for legacy links.